RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have earned an average recommendation of “Hold” from the nine ratings firms that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $4.00.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of RAPT Therapeutics in a research note on Monday, March 10th.

Institutional Investors Weigh In On RAPT Therapeutics

Several hedge funds have recently modified their holdings of RAPT. Medicxi Ventures Management Jersey Ltd acquired a new stake in RAPT Therapeutics in the fourth quarter valued at approximately $35,316,000. TCG Crossover Management LLC purchased a new position in shares of RAPT Therapeutics in the fourth quarter valued at $19,751,000. Orbimed Advisors LLC acquired a new stake in RAPT Therapeutics during the 4th quarter valued at $20,754,000. Foresite Capital Management VI LLC purchased a new stake in RAPT Therapeutics during the 4th quarter worth $19,750,000. Finally, RTW Investments LP purchased a new stake in RAPT Therapeutics during the 4th quarter worth $18,587,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

RAPT Therapeutics Stock Performance

Shares of RAPT opened at $0.86 on Monday. RAPT Therapeutics has a fifty-two week low of $0.79 and a fifty-two week high of $9.19. The company has a market capitalization of $113.99 million, a PE ratio of -0.31 and a beta of -0.29. The stock has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.39.

RAPT Therapeutics (NASDAQ:RAPT) last announced its quarterly earnings data on Thursday, March 6th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.69). As a group, equities research analysts forecast that RAPT Therapeutics will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.